Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question: April

Staff  |  Issue: April 2013  |  April 1, 2013

Coding Corner

Office Visit with Sacroiliac Joint Injection

A 72-year-old female patient returns to the office for a routine, follow-up visit for sacroilitis and ankylosing spondylitis. The patient reports that her lower back is stiff and has been swollen for the past three weeks. She is currently on celecoxib and ranitidine. The patient also mentioned having abdominal pain and nausea after she takes her celecoxib dose.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The rheumatologist takes a detailed history from the patient. On examination, the patient is alert and oriented. Her vital signs are normal, height 5 feet 7 inches, weight 140 pounds, and temperature 98º. Her head, eye, ear, nose, and throat exams are normal. There is no lymphadenopathy. Her lungs are clear. Her heart is at a regular rate and rhythm, no murmurs or friction rubs, also there are good peripheral pulses. Her abdomen is soft and nontender, with no mass or hepatosplenomegaly. The patient’s physical examination is remarkable for a large effusion sacroiliac joint (SI).

The physician decides to give the patient a SI injection performed via computed tomography (CT) guidance. The physician explains therapeutic options to the patient, including risks and benefits, and performs the SI injection with 10 mg of triamcinolone to the lower back region. The patient is taken off celecoxib. A new prescription for pain is prescribed and the patient is given discharge instructions on post-SI injection care and follow-up.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

click here for the answers.

Share: 

Filed under:Billing/CodingPractice Support Tagged with:Billing & CodingPractice Management

Related Articles

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

    Celecoxib Is a Safe Treatment for Arthritis

    February 20, 2017

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences